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AbsTrACT
Objective Explore relationships between systemic 
exposure to intravitreal aflibercept injection (IAI) and 
systemic pharmacodynamic effects via post hoc analyses 
of clinical trials of IAI for neovascular age-related macular 
degeneration (nAMD) or diabetic macular oedema (DME).
Methods and analysis Adults from VGFT-OD-0702.PK 
(n=6), VGFT-OD-0512 (n= 5), VIEW 2 (n=1204) and VIVID-
DME (n=404) studies were included. Validated ELISAs 
were used to measure concentrations of free and bound 
aflibercept (reported as adjusted bound) in plasma at 
predefined time points in each study. Non-compartmental 
analysis of concentration–time data was obtained with 
dense sampling in VGFT-OD-0702.PK and VGFT-OD-0512. 
Sparse sampling was used in VIEW 2 and VIVID-DME. 
Blood pressure or intrarenal function changes were also 
investigated.
results Following intravitreal administration, free 
aflibercept plasma concentrations quickly decreased once 
maximum concentrations were achieved at 1–3 days 
postdose; pharmacologically inactive adjusted bound 
aflibercept concentrations increased over a longer period 
and reached plateau 7 days postdose. Ratios of free and 
adjusted bound aflibercept decreased over time. There 
were no meaningful changes in systolic/diastolic blood 
pressure over the duration of each study at all systemic 
aflibercept exposure levels. For all treatment arms in 
VIEW 2, there was no clinically relevant change in mean 
intrarenal function from baseline at week 52. Overall, 
incidence of systemic adverse events in VIEW 2 and VIVID-
DME was low and consistent with the known safety profile 
of IAI.
Conclusion IAI administration was not associated 
with systemic effects in patients with nAMD or DME as 
measured by blood pressure or intrarenal function, two 
known pharmacologically relevant effects of anti-vascular 
endothelial growth factor.
InTrOduCTIOn
Due to the ability of vascular endothelial 
growth factor (VEGF) to promote angiogen-
esis, VEGF and its receptors are important 
therapeutic targets in vascular disease.1 
While both play major roles in physiological 
angiogenesis, they are also associated with 
pathological angiogenesis, such as in cancer2 
and retinal disease.
Currently approved anti-VEGF treatment 
options for retinal disease include intravitreal 
(IVT) aflibercept injection (IAI), ranibizumab 
and pegaptanib injections, while IVT use of 
compounded bevacizumab is used off-label. 
However, despite local IVT administration, 
which results in low systemic concentrations, 
and a considerable volume of published safety 
and efficacy data that demonstrate the safe 
and effective use of anti-VEGF agents in the 
eye, there is still some debate surrounding 
the potential for systemic effects, particularly 
cardiovascular events.
Key messages
What is already known about this subject?
 ► Intravitreally administered vascular endothelial 
growth factor (VEGF) inhibitors like aflibercept, ra-
nibizumab and bevacizumab are bioavailable in the 
systemic circulation. Systemic VEGF concentrations 
decrease to a variable extent and duration under 
these treatments.
What are the new findings?
 ► Systemic concentrations of free aflibercept after in-
travitreal administration of the approved dose of 2 
mg are too low to elicit pharmacodynamic effects 
as shown for blood pressure or intrarenal function, 
two known pharmacologically relevant effects of 
anti-VEGF.
How might these results change the focus of 
research or clinical practice?
 ► The pharmacokinetic/pharmacodynamic data pre-
sented in this paper further support the favourable 
safety profile of aflibercept and dispel concerns re-
lated to systemic side effects after intravitreal ad-
ministration of aflibercept at the approved dose.
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Initial uncertainty was raised by the pivotal ranibi-
zumab studies, MARINA (Minimally Classic/Occult 
Trial of the Anti-VEGF Antibody Ranibizumab in the 
Treatment of Neovascular Age-Related Macular Degen-
eration) and ANCHOR (Anti-VEGF Antibody for the 
Treatment of Predominantly Classic Choroidal Neovas-
cularization in Age-Related Macular Degeneration).3–5 
In both studies there was a slight increase in the inci-
dence of myocardial infarction and stroke in patients 
receiving IVT ranibizumab compared with controls.3–5 
The 2-year results of the Diabetic Retinopathy Clinical 
Research Network comparative effectiveness Protocol 
T study indicated an imbalance in the number of Anti-
platelet Trialists’ Collaboration (APTC)-defined arterial 
thromboembolic events (ATE) for patients in the ranibi-
zumab arm compared with the IAI and bevacizumab 
arms.6 In contrast, the Comparison of Age-related 
Macular Degeneration Treatment Trials reported that 
more patients receiving IVT bevacizumab experienced 
multiple systemic serious adverse events (AE) than those 
receiving ranibizumab,7 8 while the Inhibit VEGF in 
Age-related Choroidal Neovascularization trial reported 
no differences between bevacizumab and ranibizumab in 
the proportion of patients experiencing serious systemic 
AEs.9 In the VIEW studies there were no differences 
between aflibercept and ranibizumab in the overall inci-
dence of systemic (non-ocular) AEs or serious AEs.10 
Whether these imbalances between agents represent true 
findings, or are due to chance, has yet to be fully eluci-
dated. Additionally, while there are notable differences 
in systemic pharmacokinetics and pharmacodynamics 
of anti-VEGF treatments following IVT administration, 
it is not known whether these differences translate into 
differences in systemic effects.
It has been reported that ranibizumab (a 48 kDa 
monovalent monoclonal antibody fragment containing 
an antigen-binding Fab without the Fc domain) appears 
only transiently in the systemic circulation and is rapidly 
cleared, whereas bevacizumab (a 149 kDa full-length, 
bivalent monoclonal antibody against VEGF-A) and 
aflibercept (a 115 kDa recombinant fusion protein 
comprising key VEGF-binding domains of human VEGF 
receptors 1 and 2 fused to the Fc domain of human IgG1) 
have greater systemic exposure and have been reported to 
produce a reduction of free VEGF in plasma.11–13 It should 
be noted that measurement of free VEGF in plasma can 
be challenging because of platelet rupture and/or acti-
vation, which can lead to release of intracellular VEGF 
and thus increased levels of VEGF.11 In addition, it has 
been shown that presence of VEGF-binding compounds 
in samples affects the VEGF measurement by the assay 
and can impair the validity of results, in particular when 
samples with different anti-VEGF drugs are compared.14
In a previous preclinical study, aflibercept has demon-
strated a higher binding affinity to VEGF (and placental 
growth factor) than either ranibizumab or bevacizumab.15 
Due to its intact Fc region, aflibercept is subject to rescue 
and recycling by the neonatal Fc receptor in endothelial 
cells, a process known to slow elimination of protein ther-
apeutics containing an Fc domain.11
After IVT injection, aflibercept is systemically available 
in two distinct forms: free and bound. The free form 
of aflibercept is the active drug moiety and is capable 
of binding endogenous VEGF in a 1:1 stoichiometry to 
form a stable, inert VEGF:aflibercept complex (referred 
to as ‘bound’ aflibercept). Bound aflibercept is incapable 
of further VEGF binding and is thus biologically inac-
tive. Aflibercept binds VEGF with a high affinity, with an 
equilibrium dissociation constant of 0.49 pM. This high 
affinity is attributable to fast association rates (k
a
/105
= 410/(Mˑs)) and slow dissociation rates (k
d
/10-5 = 2/
(Mˑs)) of aflibercept to VEGF-A
165
.16 As a result of this 
slow dissociation rate, once bound to VEGF, there is virtu-
ally no release of aflibercept from this stable complex; this 
finding is in contrast to the considerably faster dissocia-
tion rates of ranibizumab and bevacizumab from VEGF.
The aim of the current analysis was to determine, 
using established and known sensitive biological indices 
of systemic VEGF inhibition, the relationship between 
systemic exposure to aflibercept after IVT administration 
and systemic pharmacodynamic effects of IAI in patients 
enrolled in clinical trials of IAI for neovascular age-re-
lated macular degeneration (nAMD) or diabetic macular 
oedema (DME).
MeTHOds
Participants
Adult patients included in clinical trials of IAI for nAMD 
or for DME were included in this analysis. All patients 
provided informed consent to participate in the clinical 
trials; this consent covers the current analysis.
study design
Analyses of studies in the IAI clinical trial database that 
included pharmacokinetic and/or pharmacodynamic 
data were conducted; the following trials were included: 
VGFT-OD-0702.PK, VGFT-OD-0512, VIEW 2 and 
VIVID-DME.
VGFT-OD-0702.PK was a pharmacokinetic exten-
sion study of the US-based clinical trial VGFT-OD-0702 
(NCT00527423), a randomised, single-masked phase II 
study comprising patients with nAMD previously enrolled 
in clinical trials of IAI. Patients were treated with 2 mg 
IAI every 8 weeks after their previous treatment in study 
VGFT-OD-0702. Pharmacokinetic samples were taken 
after first injection only.
VGFT-OD-0512 (NCT00320814) was a phase I, 
US-based exploratory, 6-week open-label study in patients 
aged ≥18 years with DME who were treated with IAI 4.0 
mg. Blood samples for pharmacokinetic analysis were 
collected at screening (visit 1) through day 155 (visit 8).
VIEW 2 (NCT00637377) was a phase III, randomised, 
double-masked, active-controlled trial conducted in in 
Europe, Asia, Australia and South America. Patients aged 
≥50 years with nAMD were included in this trial. IAI was 
administered monthly at a dose of 0.5 mg every 4 weeks 
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or 2 mg every 4 weeks, or 2 mg every 8 weeks after three 
initial monthly injections, and compared with monthly 
0.5 mg ranibizumab.10
VIVID-DME (NCT01331681) was a phase III, 
randomised, double-masked, active-controlled, 148-week 
trial conducted in Europe, Japan and Australia. Patients 
aged ≥18 years with DME were included and randomised 
1:1:1 to receive either IAI 2 mg every 4 weeks, IAI 2 mg 
every 8 weeks (after five initial monthly doses) or macular 
laser photocoagulation. The study designs of VIEW 2 and 
VIVID-DME have previously been fully described.10 17
bioanalytical methods
Validated ELISAs were used to measure concentrations 
of free and bound aflibercept in the plasma of patients 
treated with IAI at predefined time points in each study. 
The free aflibercept ELISA measured systemic concentra-
tions of aflibercept that were not in complex with VEGF, 
while the bound aflibercept ELISA measured systemic 
concentrations of aflibercept that were bound to endog-
enous VEGF to form a VEGF:aflibercept complex. The 
sum of both free and bound aflibercept is referred to as 
total aflibercept.
The assay for bound aflibercept was calibrated using 
the VEGF:aflibercept standards; the results are reported 
for bound aflibercept as weight per volume (eg, µg/L) of 
the complex (VEGF:aflibercept). Since 1 µg of complex 
(VEGF:aflibercept) equals 0.717 µg of aflibercept and 
0.283 µg of VEGF, the concentration of the complex was 
multiplied by 0.717 to give an ‘adjusted bound’ aflibercept 
concentration, which is the concentration of aflibercept 
in the VEGF:aflibercept complex and is reported herein. 
The lower limits of quantitation (LLOQ) for free and 
adjusted bound aflibercept were 15.6 and 31.5 µg/L, 
respectively. For the calculation of arithmetic means, an 
analyte concentration below the LLOQ was set to zero. 
All valid concentration values were used for calculation 
of arithmetic means.
Pharmacokinetics/pharmacodynamics
Non-compartmental analysis of concentration–time 
data obtained with dense sampling was undertaken in 
VGFT-OD-0702.PK and VGFT-OD-0512. With this type 
of analysis, pharmacokinetic parameters like area under 
the curve (AUC) and maximum observed concentration 
(C
max
) are calculated based directly on the measured 
concentration–time data without model-based assump-
tions about body compartments of the drug. Plasma 
samples for free and bound aflibercept concentrations 
were collected at prespecified time points up to 28 
and 154 days after administration, respectively. Sparse 
sampling for pharmacokinetics was used in VIEW 2 
and VIVID-DME. Sampling time points are described 
in online supplementary appendix table 1. All samples 
for pharmacokinetic analyses were collected, processed 
and stored under conditions proven to ensure adequate 
analyte stability.
Any changes in systolic/diastolic blood pressure, 
hypertension occurrence or intrarenal function change 
(measured using the urine protein:creatinine ratio 
[UPCR]),18 19 determined in single voided samples taken 
from baseline to end of study, were also investigated. 
Urine samples were obtained before performing fluores-
cence angiography to avoid artificial elevations in urine 
protein values.
statistical analysis
Analyses of VGFT-OD-0702.PK, VGFT-OD-0512, VIEW 2 
and VIVID-DME were based on available data for each 
study. All variables were analysed descriptively with 
appropriate statistical methods/categorical variables by 
frequency tables (absolute and relative frequencies) and 
continuous variables by sample statistics (ie, mean, SD, 
minimum and maximum).
resulTs
Patients
Key patient characteristics and demographics for 
the VGFT-OD-0702.PK, VGFT-OD-0512, VIEW 2 and 
VIVID-DME studies can be found in online supplemen-
tary appendix table 2.
Pharmacokinetics
VGFT-OD-0702.PK
A total of 10 plasma samples per patient were taken from 
six patients. Of the analysed plasma samples, three of the 
six patients had detectable concentrations of free afliber-
cept; however, the concentrations of free aflibercept 
were very low (≤54.0 µg/L) (figure 1, top). The resulting 
exposure in terms of AUC was therefore also very low and 
variable between patients. Only two patients had >1 quan-
tifiable sample after C
max
.
Area under the plasma concentration–time curve up to 
the last measurable concentration (AUC
last
) ranged from 0 
to 0.474 day·mg/L, with a median value of 0.022 day·mg/L 
and a mean of 0.119 day·mg/L. C
max
 ranged from 0 to 54 
µg/L, with a median value of 15 µg/L and a mean value 
of 19 µg/L (observed within 1–3 days after a 2 mg IVT 
injection). The concentrations of free aflibercept declined 
rapidly thereafter (within 7–14 days after IVT administra-
tion) to concentrations below the LLOQ (15.6 µg/L). The 
terminal elimination half-life (t
½
) could not be calculated 
by non-compartmental analysis from this study due to 
insufficient data, but was obviously much shorter than for 
adjusted bound or total aflibercept (figure 1, top).
The exposure to adjusted bound aflibercept (AUC
last
) 
was low, ranging from 2.12 to 6.71 day·mg/L (median: 
4.67 day·mg/L; mean: 4.43 day·mg/L), while C
max
 
ranged from 100 to 286 µg/L (median: 193 µg/L; mean: 
186 µg/L). The vast majority of the total aflibercept in 
the circulation after administration of IAI was in the inac-
tive, bound form.
VGFT-OD-0512
For the pharmacokinetic analysis of aflibercept concen-
trations in VGFT-OD-0512, eight samples were collected 
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Figure 1 Mean observed log-scaled concentration of 
aflibercept (free and adjusted bound) following intravitreal 
administration in the VGFT-OD-0702.PK (top) and 
VGFT-OD-0512 (bottom) studies. LLOQ, lower limit of 
quantification.
in each of the five patients over 154 days after single 
administration of 4 mg IAI. Free aflibercept concentra-
tions were only detectable in plasma at two time points 
after administration (2 and 7 days after administration) 
(figure 1, bottom). The maximum detected concentra-
tions of free aflibercept were 92 and 36 µg/L on study 
days 3 and 8, that is, 2 and 7 days after administration, 
respectively. The corresponding mean concentrations of 
free aflibercept were 50 and 27 µg/L, respectively. The 
concentrations of adjusted bound aflibercept in plasma 
were quantifiable between 2 and 42 days after adminis-
tration and consistently higher than the free aflibercept 
concentration. Total aflibercept concentrations were 
primarily a reflection of the pharmacologically inactive 
bound moiety.
VIEW 2
After administration of IAI 2 mg every 4 weeks and 2 mg 
every 8 weeks, the concentrations of free aflibercept in 
plasma were quantifiable in a minority of samples per 
time point; however, concentrations were very low and 
close to the analytical limits and were above the LLOQ in 
<30% of the patients (table 1). C
max
 was observed 1 week 
after dosing, but concentrations of free aflibercept had 
declined to non-quantifiable concentrations in nearly all 
patients by 4 weeks after dosing. Repeated administration 
of IAI 2 mg every 4 weeks and 2 mg every 8 weeks did not 
result in accumulation of free aflibercept in plasma.
Exploratory subpopulation analysis revealed no clin-
ically relevant differences in free or bound aflibercept 
concentrations in plasma with respect to age, sex, body 
mass index, creatinine clearance or geographic region 
(Europe and Japan).
For the lowest dose group of 0.5 mg, only two indi-
vidual plasma samples obtained in the 167 patients with 
pharmacokinetic sampling in this group had free afliber-
cept concentrations above the LLOQ, that is, 1–4 hours 
after the first administration (25.3 µg/L) and in week 12 
(31.2 µg/L). Therefore, pharmacokinetic results of this 
dose group are not further discussed in this section.
Adjusted bound aflibercept concentrations >LLOQ 
were observed in plasma starting 1 week after admin-
istration of IAI. C
max
 was observed 4 weeks after the 
third administration of IAI 2 mg every 4 weeks (median 
concentration 120 µg/L after a dose of 2 mg). Following 
administration of IAI 2 mg every 4 weeks, mean adjusted 
bound aflibercept concentrations increased by approx-
imately 1.5-fold between weeks 1 and 12. There was 
no further increase in the mean concentrations of IAI 
in plasma beyond week 12 with IAI 2 mg every 4 weeks 
dosing; however, after IAI 2 mg every 8 weeks dosing, 
the systemic adjusted bound aflibercept concentrations 
declined by approximately 30% in the 8 weeks postdose 
(compared with 4 weeks postdose).
VIVID-DME
Similar to VIEW 2, after administration of IAI 2 mg every 
4 weeks and 2 mg every 8 weeks, the concentration of 
free aflibercept in plasma was low and below the LLOQ 
in most patients (table 1); at the time point of C
max
 (days 
2–4), about 50% of the concentrations were not quanti-
fiable.
Repeated administration of IAI 2 mg every 4 weeks 
or 2 mg every 8 weeks did not result in accumulation of 
free aflibercept in plasma. Adjusted bound aflibercept 
concentrations were observed in plasma 2–4 days after 
administration of IAI. C
max
 was observed at week 24 (ie, 
4 weeks after the sixth administration of the IAI 2 mg 
every 4 weeks dosing regimen; note that no pharmaco-
kinetic sample was taken in week 12 of this study) and 
at week 52 (ie, 4 weeks [half the dosing interval] after 
the ninth administration of the IAI 2 mg every 8 weeks 
dosing regimen), with mean values of approximately 150 
and 100 µg/L, respectively.
Pharmacodynamics
After IVT aflibercept administration, there were no 
meaningful changes from baseline in systolic blood pres-
sure over the duration of the studies, and no clinically 
relevant differences between treatments or indications 
(online supplementary appendix figure 1). Similar 
results were observed for diastolic blood pressure (data 
not shown).
In patients treated with IAI in VIEW 2, blood pressure 
was evaluated relative to free or adjusted bound afliber-
cept concentrations in plasma. For this analysis, time 
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Table 1 Concentration–time data for free aflibercept (µg/L) in the VIEW 2 and VIVID-DME studies over 52 weeks—all patients 
(SAF)
VIEW 2 study
Time
Aflibercept*
IAI 2 mg every 4 weeks IAI 2 mg every 8 weeks
Number of observations/
number of
observations >LLOQ Mean±SD (range)†
Number of observations/
number
of observations >LLOQ
Mean±SD 
(range)†
Week 0, predose 169/0 0‡ 168/0 0‡
Week 0, 1–4 hours postdose 165/5 1.95±13.3 (0–148) 165/6 1.91±11.9 
(0–124)
Week 1 169/39 4.74±8.96 (0–35.0) 166/52 10.4±38.9 
(0–473)
Week 4, predose 170/0 0‡ 167/3 0.65±5.66 
(0–67.4)
Week 12, predose 164/2 0.27±2.51 (0–27.8) 162/0 0‡
Week 48, predose 151/1 0.12±1.43 (0–17.6) 157/0 0‡
Week 48, 1–4 hours postdose 150/5 0.81±4.92 (0–48.3) 155/4 0.97±6.93 
(0–70)
Week 52, predose 150/0 0‡ 157/0 0‡
VIVID-DME study
Time
Aflibercept‡
IAI 2 mg every 4 weeks IAI 2 mg every 8 weeks
Number of observations/
number of
observations >LLOQ Mean±SD (range)
Number of observations/
number
of observations >LLOQ
Mean±SD 
(range)
Baseline, predose 129/1 0.20±2.29 (0–26.0) 128/0 0‡
Week 0, 1–4 hours postdose 127/3 1.30±11.8 (0–131) 128/3 2.21±17.1 
(0–171)
Week 0, 2–4 days postdose§ 125/62 15.8±20.0 (0–103) 125/73 21.1±24.9 
(0–129)
Week 24, predose 125/0 0‡ 130/0 0‡
Week 52, predose 121/1 0.17±1.92 (0–21.1) 119/0 0‡
*For the 0.5 every 4 weeks dose group only two individual plasma samples had free aflibercept concentrations >LLOQ, and are thus not 
presented here.
†Maximum mean concentration:arithmetic mean.
‡All values <LLOQ.
§Samples were taken at visit 2 only.
IAI, intravitreal aflibercept injection; LLOQ, lower limit of quantification; SAF, safety analysis set.
points of C
max
 were selected, that is, week 1 for free afliber-
cept and week 12 for adjusted bound aflibercept. Systemic 
concentrations of free or adjusted bound aflibercept did 
not correlate with blood pressure changes (figure 2). 
Blood pressure changes in patients with free or bound 
aflibercept concentrations below the LLOQ were in the 
same range as those with free aflibercept concentrations 
>LLOQ and up to the individual observed maximum of 
about 110 µg/L of free aflibercept and about 410 µg/L 
for adjusted bound aflibercept. Furthermore, there is not 
any indication for a trend of blood pressure increase with 
increasing aflibercept concentrations or IVT dose levels.
The relationship between free or bound aflibercept 
concentrations and the occurrence of blood pressure-re-
lated AEs, for example, hypertension was explored over 
the entire first year of VIEW 2, that is, the entire span 
of blood sampling for pharmacokinetics (figure 3). All 
aflibercept concentrations (observed range along the 
y-axis) of patients experiencing such an AE at any time 
during the first year of the study (time after first admin-
istration along the x-axis) were indicated by red symbols, 
while concentrations of patients without such event are 
shown in blue. The even distribution of the red symbols 
in the same range as the blue symbols indicates that there 
is no correlation between the concentrations of free or 
adjusted bound aflibercept in plasma with the occur-
rence of blood pressure-related AEs. In contrast, free 
aflibercept above 50 µg/L and adjusted bound afliber-
cept concentrations above 250 µg/L were all observed in 
patients without a blood pressure-related AE (figure 3).
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Figure 2 Relationship between the absolute change 
in systolic blood pressure (SBP) from baseline and the 
concentration of free (top) and adjusted bound (bottom) 
aflibercept in the VIEW 2 study. 0.5q4, 0.5 mg every 4 weeks; 
2q4, 2 mg every 4 weeks; 2q8, 2 mg every 8 weeks; BP, 
blood pressure; IAI, intravitreal aflibercept injection; LLOQ, 
lower limit of quantification.
Figure 3 Distribution of free (top) and adjusted bound 
(bottom) aflibercept concentrations over time by occurrence 
of any hypertension event in the VIEW 2 study.
Figure 4 Distribution of free (top) and adjusted bound 
(bottom) aflibercept concentrations over time by occurrence 
of any hypertension event in the VIVID-DME study.
Similarly, in VIVID-DME, systemic aflibercept exposure 
did not correlate with blood pressure changes (figure 4). 
Also when patients were stratified by age, there were no 
differences in systemic effects observed (online supple-
mentary appendix figure 2).
For all treatment arms in VIEW 2, there was no clin-
ically relevant change in intrarenal function from 
baseline at week 52, with slight numeric decrease in 
mean UPCR over all IAI groups (see ‘IAI total’ in online 
supplementary appendix table 3) and mean changes 
in UPCR per individual treatment group (increase or 
decrease) in the range of ~1/10 of the SDs.
safety
Overall, the incidence of systemic AEs, including 
APTC-defined ATEs, was low in VIEW 2 and VIVID-DME 
(online supplementary appendix table 4).
In VIEW 2, hypertension-related events (as treat-
ment-emergent AEs [TEAE] and serious TEAEs, 
respectively [based on MedDRA SMQ]) were experi-
enced by 82 (9.0%) and 4 (0.4%) IAI patients, and by 29 
(10.0%) and 0 (0.0%) ranibizumab patients.
The most frequently reported ocular TEAEs in the 
study eye of patients receiving IAI (combined group) 
in VIEW 2 were reduced visual acuity (10.2%), conjunc-
tival haemorrhage (10.0%) and retinal haemorrhage 
(9.2%). In patients receiving ranibizumab, the most 
frequently reported ocular TEAEs in the study eye 
were retinal haemorrhage (10.0%), eye pain (9.3%), 
conjunctival haemorrhage (7.9%) and macular degen-
eration (7.9%).
 o
n
 June 25, 2020 by guest. Protected by copyright.
http://bmjophth.bmj.com/
BM
J O
pen O
phth: first published as 10.1136/bmjophth-2018-000185 on 20 March 2019. Downloaded from 
7Kaiser PK, et al. BMJ Open Ophth 2019;4:e000185. doi:10.1136/bmjophth-2018-000185
Open access
Similarly in VIVID-DME, hypertension-related TEAEs 
and serious TEAEs were experienced by 44 (16.2%) 
and 2 (0.7%) IAI patients, and by 19 (14.3%) and 0 
(0.0%) laser patients, respectively.
The most frequently reported ocular TEAEs in the 
study eye of patients receiving IAI (combined group) in 
VIVID-DME were conjunctival haemorrhage (22.9%) 
and an increase in intraocular pressure (6.6%). In 
patients receiving laser, the most frequently reported 
ocular TEAEs in the study eye were abnormal visual 
acuity tests (14.3%) and reduced visual acuity (12.8%).
Overall AEs were consistent with the known safety 
profile of IAI in nAMD.
dIsCussIOn
The objective of this paper was to explore whether afliber-
cept, a potent VEGF inhibitor released at a low rate in 
the systemic circulation resulting in low or undetectable 
systemic concentrations after IVT administration at the 
approved dose of 2 mg, could be associated with systemic 
pharmacodynamic effects known to be related to VEGF 
inhibition.
IAI is approved in a number of indications including 
nAMD, DME, macular oedema following retinal vein 
occlusion and myopic choroidal neovascularisation; 
however, for the purpose of this pharmacokinetic/phar-
macodynamic analysis the focus was on the two main 
indications, nAMD and DME. Available data from four 
studies with different pharmacokinetic sampling schemes 
were used. The two smaller studies VGFT-OD-0702.PK 
(nAMD) and VGFT-OD-0512 (DME) with dense pharma-
cokinetic sampling provided a full concentration–time 
profile for aflibercept plasma concentrations in a limited 
number of patients. In contrast, the large phase III 
clinical studies VIEW 2 (nAMD) and VIVID-DME were 
dependent on a limited number of sampling time points 
for drug concentration measurement in each patient to 
make them compatible with a phase III setting; however, 
this allowed sampling in a larger number of patients and 
therefore exploration of the relationship between phar-
macokinetics and pharmacodynamics as well as AEs.
Based on evidence from oncology studies, using large, 
intravenously administered doses of anti-VEGF agents, 
blood pressure increases and changes in intrarenal 
function (UPCR) have become established sensitive 
markers of systemic vascular VEGF inhibition.20 21 Both 
of these parameters were monitored during clinical 
studies with IAI. Although the interindividual vari-
ability in UPCR18 is generally high in elderly patients 
(due to the higher number of concomitant disorders 
vs younger patients), results suggest that there is no 
difference in renal protein loss following IVT treat-
ment with aflibercept compared with baseline. These 
results are also in line with postmarketing data, which 
do not support a causal association between IAI and 
development or worsening of renal impairment (Bayer 
data on file).
The current analyses were conducted for both free 
and bound aflibercept. Following IVT administra-
tion, aflibercept is slowly released from the eye into 
the systemic circulation, where it is predominantly 
observed in its biologically inactive bound form. While 
free aflibercept is detectable in plasma 1–2 weeks after 
administration and does not accumulate after repeated 
administration every 4 weeks, bound aflibercept accu-
mulates after repeated administration and reaches a 
steady state 4 weeks after the third IAI administration, 
that is, at week 12. The ratio of free and bound afliber-
cept is not constant, but decreases over time as the 
concentration of free aflibercept increases to C
max
 at a 
faster rate than bound aflibercept and then decreases 
quickly thereafter, while bound aflibercept concentra-
tions plateau. As such, total aflibercept concentrations 
(defined as the sum of free and bound aflibercept) 
should not be used as a surrogate for active drug 
concentrations (as it is often used for small molecules 
bound to plasma proteins that show no concentration 
dependence of protein binding).
Overall, systemic pharmacokinetic and pharmaco-
dynamic parameters of aflibercept were similar across 
both nAMD and DME indications and consistent across 
the four studies included in this analysis as well as with 
recently published data on free aflibercept concen-
trations after IAI.22 Free aflibercept concentrations 
obtained 1 week after the first IAI administration were 
used to explore the potential pharmacokinetic/phar-
macodynamic relationship for the pharmacologically 
active moiety. Although pharmacologically inactive, the 
relationship between bound aflibercept and potential 
systemic pharmacodynamic markers of VEGF inhi-
bition at week 12 were also explored for the sake of 
completeness.
Based on data fromVGFT-OD-0702.PK (comparison 
of mean AUC values), only 3% of the total aflibercept 
in the plasma was related to free aflibercept. However, 
the ratio of free and total aflibercept concentrations 
in the plasma is not constant over time (figure 1), but 
shows a faster elimination of free versus total afliber-
cept. As a result, only free aflibercept is present during 
the first week after administration (and only measur-
able in half of the patients investigated); most of the 
time total aflibercept concentrations exclusively reflect 
inactive bound aflibercept. Free aflibercept exhibits 
non-linear pharmacokinetics consistent with saturable, 
target-mediated drug disposition and is predominantly 
cleared by relatively rapid, specific and saturable 
high-affinity binding to VEGF, but also via slower, 
non-saturable clearance mechanisms. It is thought that 
these latter mechanisms are proteolytic catabolism 
processes that affect both free and bound aflibercept. 
In contrast, bound aflibercept is cleared by linear 
proteolytic processes. Compared with free aflibercept, 
the slower elimination of bound aflibercept results in 
quantifiable concentrations of adjusted bound—and 
consequently total—aflibercept over a longer period of 
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time. Quantifiable concentrations of bound aflibercept 
were therefore already at predose values observed in the 
pharmacokinetic substudy VGFT-OD-0702.PK because 
these patients were pretreated with IAI in VGFT-OD-
0702 before entering VGFT-OD-0702.PK.
In VIEW 2, there was no accumulation of free afliber-
cept in plasma, suggesting that longer treatment 
duration is not likely to be associated with an increased 
risk of systemic side effects.
Notably, IVT aflibercept did not have any effect 
on blood pressure or kidney function in any of these 
studies; in addition, there was no association with regard 
to the systemic concentrations of free or bound afliber-
cept at the patient level. There were also no signals for 
any difference in systemic effects between age groups. 
This absence of any systemic pharmacodynamic effects 
following treatment with IAI is in line with a recent 
publication23 and with the understanding of the physio-
logical role of VEGF. VEGF, a 27 kDa macromolecule, is 
an autocoid and thus is synthesised at its intended site of 
action in the vascular endothelium. Platelets sequester 
the majority of VEGF released into the systemic circu-
lation and thus restrict the activity of VEGF to its site 
of synthesis.24 This supports the hypothesis that VEGF 
concentrations in plasma have no physiological rele-
vance to any downstream processes. Furthermore, it 
should be considered that only free aflibercept can 
bind VEGF, while bound VEGF is pharmacologically 
inert and thereby unable to bind further VEGF. The 
small amount of free aflibercept that is released into 
the systemic circulation following IVT injection can, 
even at its maximum, only bind a small fraction of the 
VEGF produced daily by the body.25
The absence of any systemic pharmacodynamic 
effects is also consistent with the low number of 
systemic AEs, including hypertension and APTC-de-
fined ATEs, showing no difference between aflibercept 
and control. These findings appear to be in line with 
what has previously been reported in the literature. In 
a comprehensive review of safety data from 10 phase II 
and III clinical trials (>4000 patients contributing >7000 
patient-years at risk) of IAI in nAMD, macular oedema 
secondary to central/branch retinal vein occlusion, 
and DME, the incidence of systemic AEs (including 
adjudicated APTC-defined ATEs) was low and similar 
across the IAI and control groups.26
In conclusion, based on the findings presented here, 
and given the sensitivity of blood pressure changes 
and kidney function as a proxy for systemic anti-
VEGF activity, there was no indication that the use of 
IVT aflibercept was associated with systemic effects in 
patients with nAMD or DME.
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